Co-occurrence of Neuromyelitis Optica Spectrum Disorder and Idiopathic Multicentric Castleman Disease Successfully Treated with Tocilizumab: A Case Report

被引:0
|
作者
Wada, Takuma Tsuzuki [1 ]
Yokota, Kazuhiro [1 ]
Okada, Mariko [2 ]
Ichimura, Takaya [3 ]
Ueno, Takehito [1 ]
Okumura, Nobuhito [1 ]
Osawa, Iichiro [4 ]
Inoue, Kaiji [4 ]
Akiyama, Yuji [1 ]
Nakazato, Yoshihiko [2 ]
Sasaki, Atsushi
Yamamoto, Toshimasa [2 ]
Mimura, Toshihide [1 ]
机构
[1] Saitama Med Univ, Fac Med, Dept Rheumatol & Appl Immunol, Irama, Japan
[2] Saitama Med Univ, Fac Med, Dept Neurol, Saitama, Japan
[3] Saitama Med Univ, Fac Med, Dept Pathol, Saitama, Japan
[4] Saitama Med Univ Hosp, Dept Radiol, Saitama, Japan
关键词
neuromyelitis optica spectrum disorder; Castleman disease; interleukin-6; tocilizumab; ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; DIAGNOSTIC-CRITERIA; EFFICACY; PLASMABLASTS; SATRALIZUMAB; AQUAPORIN-4; SAFETY;
D O I
10.2169/internalmedicine.4503-24
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We herein report a 52-year-old woman with anti-aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and idiopathic multicentric Castleman disease (iMCD) who was successfully treated with tocilizumab, a humanized anti-human interleukin (IL)-6 receptor monoclonal antibody. This is the first report of a case of coexisting NMOSD and iMCD. IL-6 is involved in the pathogenesis of both NMOSD and iMCD, and tocilizumab is effective against both diseases. By treating the patient with tocilizumab, the lung lesions due to iMCD improved, and the neurological symptoms of NMOSD did not recur.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report
    Kosmidis, Christoforos S.
    Mystakidou, Chrysi Maria
    Koimtzis, Georgios
    Papadopoulou, Evanthia
    Theodorou, Vasiliki
    Katsios, Nikolaos Iason
    Georgakoudi, Eleni
    Sevva, Christina
    Charalampous, Ioannis
    Varsamis, Nikolaos
    Koulouris, Charilaos
    Michael, Christina
    Papadopoulos, Konstantinos
    Anthimidis, Georgios
    Baka, Sofia
    MEDICINA-LITHUANIA, 2022, 58 (09):
  • [42] Interleukin-6 Blockade with Tocilizumab in Idiopathic Multicentric Plasma Cell Variant Castleman Disease: Case Report
    Fernando Naranjo-Saltos
    Martin Lescano Ruiz
    Yanael Arce
    Heidi Angela Fernandez
    SN Comprehensive Clinical Medicine, 5 (1)
  • [43] Neuromyelitis optica spectrum disorder initiated with hemiageusia and pruritus: A case report
    Wang, RuiJin
    Qi, Dong
    Zhang, YongBo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 348 (1-2) : 288 - 289
  • [44] Paraneoplastic neuromyelitis optica spectrum disorder: A case report and review of the literature
    Annus, Adam
    Bencsik, Krisztina
    Obal, Izabella
    Kincses, Zsigmond Tamas
    Tiszlavicz, Laszlo
    Hoeftberger, Romana
    Vecsei, Laszlo
    JOURNAL OF CLINICAL NEUROSCIENCE, 2018, 48 : 7 - 10
  • [45] Neuromyelitis Optica Spectrum Disorder With Hyponatremia as an Initial Presentation: A Case Report
    Yang, Siqi
    Tian, Juan
    Huang, Hui
    Yan, Zhe
    CLINICAL THERAPEUTICS, 2021, 43 (12) : 2168 - 2172
  • [47] Hydrocephalus in neuromyelitis optica spectrum disorder: A case report and literature review
    Chiba, T.
    Tsukita, K.
    Watanabe, G.
    Ikenouchi, H.
    Nakamura, N.
    Suzuki, Y.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 1066 - 1066
  • [48] Neuromyelitis optica spectrum disorder in a patient with ankylosing spondylitis: A case report
    Salari, Mehri
    Harofteh, Bahareh Zaker
    Etemadifar, Masoud
    CLINICAL CASE REPORTS, 2023, 11 (06):
  • [49] Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
    Lehrieder, Dominik
    Zapantis, Nikolaos
    Pham, Mirko
    Schuhmann, Michael Klaus
    Haarmann, Axel
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [50] Case report: Hyponatremia is an initial presentation of Neuromyelitis optica spectrum disorder
    Meng, Huaxing
    Wang, Jing
    Hou, Jiaqi
    Liu, Ruiqin
    Zhang, Meini
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2024, 134 (11) : 1399 - 1402